- Home
- MUC vs AMPH Comparison
MUC vs AMPH Comparison
Compare MUC & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUC
- AMPH
- Stock Information
- Founded
- MUC 1997
- AMPH 1996
- Country
- MUC United States
- AMPH United States
- Employees
- MUC N/A
- AMPH N/A
- Industry
- MUC Investment Bankers/Brokers/Service
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- MUC Finance
- AMPH Health Care
- Exchange
- MUC Nasdaq
- AMPH Nasdaq
- Market Cap
- MUC 972.0M
- AMPH 1.1B
- IPO Year
- MUC N/A
- AMPH 2014
- Fundamental
- Price
- MUC $10.26
- AMPH $29.83
- Analyst Decision
- MUC
- AMPH Buy
- Analyst Count
- MUC 0
- AMPH 5
- Target Price
- MUC N/A
- AMPH $36.20
- AVG Volume (30 Days)
- MUC 292.8K
- AMPH 621.6K
- Earning Date
- MUC 01-01-0001
- AMPH 08-07-2025
- Dividend Yield
- MUC 4.19%
- AMPH N/A
- EPS Growth
- MUC N/A
- AMPH N/A
- EPS
- MUC N/A
- AMPH 2.68
- Revenue
- MUC N/A
- AMPH $722,679,000.00
- Revenue This Year
- MUC N/A
- AMPH $0.92
- Revenue Next Year
- MUC N/A
- AMPH $5.55
- P/E Ratio
- MUC N/A
- AMPH $11.14
- Revenue Growth
- MUC N/A
- AMPH 1.37
- 52 Week Low
- MUC $9.19
- AMPH $20.39
- 52 Week High
- MUC $11.30
- AMPH $53.96
- Technical
- Relative Strength Index (RSI)
- MUC 52.44
- AMPH 76.06
- Support Level
- MUC $10.23
- AMPH $29.64
- Resistance Level
- MUC $10.35
- AMPH $31.23
- Average True Range (ATR)
- MUC 0.08
- AMPH 1.16
- MACD
- MUC 0.02
- AMPH 1.10
- Stochastic Oscillator
- MUC 74.29
- AMPH 87.08
About MUC Blackrock MuniHoldings California Quality Fund Inc.
BlackRock MuniHoldings California Quality Fund Inc is a diversified, closed-end management investment firm. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income taxes and California personal income taxes.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.